Tumour Re-engineering
Combining different anti-cancer immunotherapies is currently a major focus of clinical oncology studies, but while this can increase efficacy this benefit usually comes at a price of increased, dose limiting toxicity. Because these agents are dosed systemically, they frequently cause unwanted immune inflammation in a variety of organ systems as well as in the intended tumor lesions.

Tumor re-engineering aims to overcome these issues by enabling selective delivery to and/or production of the therapeutic agent or combinations in tumor tissues where they are needed while minimizing systemic exposure. We are developing a tumor-specific immune-gene (T-SIGn) vector approach that delivers biotherapeutic gene payloads for production by the tumor cells themselves. These aim to promote anti-tumor immunity from within the lesions by targeting elements of the tumor and local lymphoid microenvironments. This presentation will use data generated with different clinical and preclinical stage T-SIGn candidates to illustrate these concepts.
Date: 6 July 2021, 12:00 (Tuesday, 11th week, Trinity 2021)
Venue: Zoom
Speaker: Manuela Zonca (PsiOxus)
Organisers: Amira Burshan (University of Oxford), Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address: sheena.lee@medsci.ox.ac.uk
Hosts: Amira Burshan (University of Oxford), Sheena Lee (MSD Business Partnerships Office)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url: https://www.eventbrite.co.uk/e/industry-insights-seminar-series-tickets-131313880351
Cost: Free
Audience: Members of the University of Oxford and the UK Biotech/Pharma industry
Editor: Sheena Lee